1-3 of 3
Manuel Pazos, II
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

First-in-Class HAT Activator (YF2) Combined with JAK/STAT Inhibitor (ruxolitinib) Unveils Potential Novel Treatment Approach for HDAC Inhibitor-Resistant CTCL

Manuel Pazos, II, Brian Estrella, Ted B. Piorczynski, Seda S. Tolu, Wenxuan Huang, Yun Kyoung Ryu, Jennifer E Amengual
Journal: Blood
Blood (2023) 142 (Supplement 1): 4184.
https://doi.org/10.1182/blood-2023-186639
Published: 2023
Journal Articles

JAK1/2 Inhibition Modulates Key Markers of Lymphomagenesis in 9p24.1 Amplified Lymphoma, Priming for Enhanced Antigenicity

Seda S. Tolu, Ted B. Piorczynski, Manuel Pazos, II, Brian Estrella, Wenxuan Huang, Yun Kyoung Ryu, Hua-Jay J. Cherng, Barbara Pro, Jennifer E. Amengual
Journal: Blood
Blood (2023) 142 (Supplement 1): 6118.
https://doi.org/10.1182/blood-2023-180875
Published: 2023
Journal Articles

Combination Epigenetic Therapy Using YF2, a First-in-Class Histone Acetyltransferase Activator, Restores Immunogenicity in Diffuse Large B-Cell Lymphoma

Ted B. Piorczynski, Yun Kyoung Ryu, Manuel Pazos, II, Wenxuan Huang, Seda S. Tolu, Brian Estrella, Jennifer E Amengual
Journal: Blood
Blood (2023) 142 (Supplement 1): 4391.
https://doi.org/10.1182/blood-2023-179271
Published: 2023